1356447-90-9
1356447-90-9
Chemical Structure
GZ-793A
- CAS. Nr.: 1356447-90-9
- Formula:C26H38ClNO4
- Molecular Weight:464.04
IUPAC Name: (R)-3-((2R,6S)-2,6-bis(4-methoxyphenethyl)piperidin-1-yl)propane-1,2-diol hydrochloride
InChIKey: FLFFCQKGCYZDOI-SJUVJREQSA-N
SMILES: OC[C@H](O)CN1[C@H](CCC[C@H]1CCC2=CC=C(C=C2)OC)CCC3=CC=C(C=C3)OC.Cl
Biological Activity: GZ-793A is an orally active and selective vesicular monoamine transporter-2 (VMAT2) inhibitor, with an Ki of 0.029 µM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH)-induced dopamine release. GZ-793A can be used for research of METH addiction[1][2][3].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
GZ-793A | 99.50% | GZ-793A is an orally active and selective vesicular monoamine transporter-2 (VMAT2) inhibitor, with an Ki of 0.029 µM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH)-induced dopamine release. GZ-793A can be used for research of METH addiction. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wilmouth CE, et al. Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats. Pharmacol Biochem Behav. 2013 Nov;112:29-33. [Content Brief]
- [2]. Nickell JR, et al. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2. Eur J Pharmacol. 2017 Jan 15;795:143-149. [Content Brief]
- [3]. Nickell JR, et al. The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Adv Pharmacol. 2014;69:71-106. [Content Brief]
